ストックスクリーナーアプリを入手
0.9747
0.87%
-0.0086
アフターアワーズ：
.98
0.0053
+0.54%
Akebia Therapeutics Inc (AKBA) 最新ニュース
BlackRock Inc. Buys Shares of 19,986,374 Akebia Therapeutics, Inc. $AKBA - MarketBeat
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - tradingview.com
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Akebia Therapeutics to Conduct Investor Meetings at the 2026 Wells Fargo Healthcare Conference in Boston - Moomoo
Nantahala Capital Management LLC Takes Position in Akebia Therapeutics, Inc. $AKBA - MarketBeat
Akebia Therapeutics (NASDAQ:AKBA) Stock Price Passes Below 200-Day Moving AverageWhat's Next? - MarketBeat
Akebia (AKBA) Market: Slides 1.39% to $0.91 for the Current Session; Key Range: the Near-Term Reference Band Stretches From $0.86 to $0.96 on the DayRTH Profile - vinanet.vn
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Given Average Rating of "Hold" by Analysts - MarketBeat
Akebia Therapeutics, Inc. Revenue Breakdown – NASDAQ:AKBA - TradingView
Piper Sandler Maintains Akebia Therapeutics(AKBA.US) With Buy Rating, Maintains Target Price $4 - Moomoo
AKBA Q2 2026 Earnings: Narrower-Than-Expected Loss Beats Estimates by 33.18%Return On Equity - vinanet.vn
AKBA Shares Rise On Clinical Pipeline Optimism As Anemia Drug Gains Traction - Stocktwits
Akebia Therapeutics CEO John P. Butler Exercises 350,000 Stock Options at $0.63 Each - Kalkine Media
Weekly Recap: Vafseo sales surge and ebribafusp Phase 2 trial start - TradingView
Akebia Therapeutics, Inc. $AKBA Shares Sold by Renaissance Technologies LLC - MarketBeat
HC Wainwright Has Negative Outlook of AKBA FY2026 Earnings - MarketBeat
Akebia Therapeutics (AKBA) AGM 2026 Summary - Quartr
Akebia Therapeutics Price Target Announced at $1.00/Share by Leerink Partners - Moomoo
Akebia Therapeutics Inc (AKBA) Stock News Today - TradingKey
Akebia Therapeutics Inc (AKBA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Akebia Therapeutics (NASDAQ:AKBA) Downgraded by Leerink Partners to "Market Perform" - MarketBeat
Akebia Therapeutics Inc (AKBA:UR): Stock Price, Quote and News - BNN Bloomberg
Akebia Therapeutics, Inc. (AKBA) Investor Outlook: Analyzing a 340% Potential Upside Amid Healthcare Innovation - DirectorsTalk Interviews
H.C. Wainwright Maintains Akebia Therapeutics(AKBA.US) With Buy Rating, Maintains Target Price $6 - Moomoo
AKBA Looks 1.6% Overvalued on GF Value™ - GuruFocus
AKBA Looks 1.2% Overvalued on GF Value™ as Market Prices in Mode - GuruFocus
Akebia Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights - The Manila Times
Akebia Therapeutics Inc (AKBA) (Q2 2026) Earnings Call Highlight - GuruFocus
Akebia Therapeutics Inc (AKBA) (Q2 2026) Earnings Call Highlights: Vafseo Surges 60% as VOICE ... - Yahoo Finance
Is Akebia Therapeutics Inc (AKBA) Overvalued After Q2 Earnings M - GuruFocus
Akebia Therapeutics Q2 Earnings Call Highlights - MarketBeat
Akebia Therapeutics (AKBA) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Akebia Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Akebia Therapeutics (NASDAQ:AKBA) Releases Earnings Results - MarketBeat
Akebia Therapeutics: Q2 Earnings Snapshot - Barchart.com
Akebia Therapeutics Inc. R (AX9.F) Q2 FY2026 earnings call transcript - Yahoo Finance
Akebia Therapeutics 2Q 2026: Revenue $49.1M, EPS $(0.03) — 10-Q Summary - TradingView
Akebia begins trial for three rare kidney diseases; data expected in 2027 - Stock Titan
Akebia Therapeutics Inc expected to post a loss of 4 cents a shareEarnings Preview - TradingView
Akebia initiates phase 2 trial for rare kidney disease drug - Investing.com
Akebia initiates phase 2 trial for rare kidney disease drug By Investing.com - Investing.com South Africa
Akebia Therapeutics Announces Initiation of a Phase 2 Basket Trial to Study Ebribafusp, a Next-Generation Complement Inhibitor in Rare Kidney Diseases - The Manila Times
Akebia Therapeutics Announces Initiation of a Phase 2 - GlobeNewswire
Akebia Therapeutics And 2 Promising Penny Stocks To Watch - webull.com
Akebia Therapeutics (AKBA) to Announce Earnings on Thursday - MarketBeat
Akebia Therapeutics to Report Second Quarter 2026 Financial Results and Discuss Recent Business Highlights - The Manila Times
Akebia Therapeutics to report Q2 2026 financial results on August 5 with a conference call. - Pluang
Akebia Therapeutics Inc (AKBA) Income Statement - tradingkey.com
Akebia Therapeutics Inc (AKBA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Akebia Therapeutics Inc (AKBA) Balance Sheet - TradingKey
Akebia Therapeutics Inc (AKBA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Akebia Therapeutics Inc (AKBA) Cash Flow - TradingKey
AKBA|Akebia Therapeutics Inc|Price:1.220| - TradingKey
Akebia Therapeutics Inc (AKBA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Akebia Therapeutics Inc (AKBA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Akebia Therapeutics Inc (AKBA) Institutional Confidence - TradingKey
AKBA|Akebia Therapeutics Inc|Price:1.290|Chg%:+0.070 - TradingKey
AKBA|Akebia Therapeutics Inc|Price:1.280| - TradingKey
Akebia Therapeutics Inc (AKBA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
1.66%
0.33%
大文字化:
|
ボリューム (24 時間):